Korean J Med.  2014 Jun;86(6):761-765.

Case Report of Everolimus-Associated DKA in a Patient with Metastatic Renal Cell Carcinoma

• Kim LK
• Ahn CH
• Lee JE
• Jung CH
• Koo BK
• Moon MK

Abstract

Everolimus, an inhibitor of the mammalian target of the rapamycin (mTOR) pathway, is widely used as an immunosuppressant for the prevention of organ rejection following transplant and to treat metastatic clear-cell type renal cell carcinoma (RCC), breast cancer, and pancreatic neuroendocrine tumors. Everolimus commonly induces metabolic abnormalities such as hyperglycemia, hypercholesterolemia, and hypertriglyceridemia due to concomitant increases in blood glucose levels via the induction of insulin resistance and a decrease in beta cell function, which both lead to insulin deficiency. Although abnormal blood glucose levels are observed in more than 50% of patients treated with Everolimus, hyperglycemia exceeding 500 mg/dL is not common and there have been no reports of Everolimus-induced acute hyperglycemic crisis conditions. Here, a novel case of Everolimus-associated diabetic ketoacidosis (DKA) in a patient with RCC is reported.

Keyword

Everolimus; DKA; Hyperglycemia; Insulin resistance; Metastatic renal cell carcinoma

MeSH Terms

Blood Glucose
Breast Neoplasms
Carcinoma, Renal Cell*
Diabetic Ketoacidosis
Humans
Hypercholesterolemia
Hyperglycemia
Hypertriglyceridemia
Insulin
Insulin Resistance
Neuroendocrine Tumors
Sirolimus
Everolimus
Blood Glucose
Insulin
Sirolimus